Sutro Biopharma (STRO) Research & Development (2017 - 2026)
Sutro Biopharma (STRO) posted Research & Development of $36.6 million for Q4 2025, down 8.06% sequentially from $39.9 million in Q3 2025, and down 48.42% YoY from $71.0 million in Q4 2024.
Sutro Biopharma (STRO) Research & Development (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported Research & Development for 9 years, with the latest figure at $36.6 million in Q4 2025.
- Quarterly Research & Development fell 48.42% year-over-year to $36.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $166.4 million (down 33.97% YoY) and the FY2025 annual result came in at $166.4 million, down 33.97% from the prior year.
- Research & Development slipped to $36.6 million in Q4 2025 per STRO's latest filing, from $39.9 million in the prior quarter.
- Over five years, Research & Development peaked at $71.0 million in Q4 2024 and troughed at $22.6 million in Q1 2021.
- A 5-year average of $42.0 million and a median of $39.6 million in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development surged 49.12% in 2024, then tumbled 48.42% in 2025.
- Over 5 years, Research & Development stood at $29.9 million in 2021, then surged by 44.13% to $43.1 million in 2022, then rose by 24.64% to $53.8 million in 2023, then soared by 32.12% to $71.0 million in 2024, then sank by 48.42% to $36.6 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $36.6 million, $39.9 million, and $38.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | 31.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.70 Mn |
| Dec 31, 2025 | 36.64 Mn |
| Sep 30, 2025 | 39.85 Mn |
| Jun 30, 2025 | 38.33 Mn |
| Mar 31, 2025 | 51.60 Mn |
| Dec 31, 2024 | 71.04 Mn |
| Sep 30, 2024 | 62.11 Mn |
| Jun 30, 2024 | 62.02 Mn |
| Mar 31, 2024 | 56.88 Mn |
| Dec 31, 2023 | 53.77 Mn |
| Sep 30, 2023 | 45.67 Mn |
| Jun 30, 2023 | 41.59 Mn |
| Mar 31, 2023 | 39.40 Mn |
| Dec 31, 2022 | 43.14 Mn |
| Sep 30, 2022 | 31.71 Mn |
| Jun 30, 2022 | 32.33 Mn |
| Mar 31, 2022 | 29.99 Mn |
| Dec 31, 2021 | 29.93 Mn |
| Sep 30, 2021 | 26.60 Mn |
| Jun 30, 2021 | 25.31 Mn |